Minoo Adib; Fakhri Navaei; Farzad Oreizi; Fereshteh Saheb-Fosoul; Vajiheh Ostadi
Volume 3, Issue 1 , March 2006, , Pages 9-14
Abstract
Background: Neonatal sepsis is a life-threatening disease with an incidence of 1 to 10 per 1000 live births and a mortality rate of 15% to 50%. The clinical signs are non-specific and indistinguishable from those caused by a variety of neonatal noninfectious disorders. Objective: The aim of this study ...
Read More
Background: Neonatal sepsis is a life-threatening disease with an incidence of 1 to 10 per 1000 live births and a mortality rate of 15% to 50%. The clinical signs are non-specific and indistinguishable from those caused by a variety of neonatal noninfectious disorders. Objective: The aim of this study was to determine the importance of CD64 expression (FcgRI), a neutrophil surface marker, in early diagnosis of neonatal sepsis. Methods: The studied population comprised of 65 neonates with gestational ages of 27 to 38 weeks, suspected of having sepsis in the first 28 days of life and 12 healthy neonates with physiologic hyperbilirubinemia. One ml of whole blood was obtained to determine CD64 expression on peripheral blood neutrophils by flow cytometry. Results: CD64 expression was significantly higher in the group with sepsis than the control groups (P < 0.001). Sensitivity and specificity of CD64 were 92.3% and 100%, respectively. The negative and positive predictive values of CD64 for identifying sepsis were 100% and 88%, respectively. Conclusion: A change in cell surface expression of CD64 on peripheral blood neutrophils may be considered as a sensitive marker for detection of neonatal sepsis if used in combination with other laboratory parameters.
Akbar Vahdati; Minoo Adib; Shirin Kashfi; Taji Afrooz; Edna Abkar
Volume 2, Issue 4 , December 2005, , Pages 208-212
Abstract
Background: Erythropoietin (EPO) was first known as a factor for red blood cell proliferation and differentiation. New studies show the effects of EPO on immune system. Objective: In this study, the effects of pretreatment with recombinant human erythropoietin (rHuEPO) on the anti-human leukocyte antibody ...
Read More
Background: Erythropoietin (EPO) was first known as a factor for red blood cell proliferation and differentiation. New studies show the effects of EPO on immune system. Objective: In this study, the effects of pretreatment with recombinant human erythropoietin (rHuEPO) on the anti-human leukocyte antibody (anti-HLA) titer were determined. Methods: Three groups of rats were sensitized with human lymphocytes. Two of the groups were given 20 or 100 IU/Kg rHuEPO after two sensitizations with human lymphocytes. Control group did not receive rHuEPO. Microlymphocytotoxicity method was used to detect anti-HLA antibodies. Results: Treatment with rHuEPO caused a significant decline in anti-HLA antibody titer compared to control group. Also, pretreatment with rHuEPO suppressed antibody response after repeated antigenic stimulation. Conclusion: Such results could be due to the effects of rHuEPO on the number or the activity of the B and the T cells. Moreover, the dose of rHuEPO and the length of treatment might affect anti-HLA antibody titer.